Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. - Wikidata - awgldk - TriplyDB

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

http://www.wikidata.org/entity/Q34650346

about

Methamphetamine administration targets multiple immune subsets and induces phenotypic alterations suggestive of immunosuppression CD28 co-stimulation down regulates Th17 development The PD-1 pathway in tolerance and autoimmunity Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1 Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy The Contribution of Immune Evasive Mechanisms to Parasite Persistence in Visceral Leishmaniasis Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role Immune checkpoint inhibitors: therapeutic advances in melanoma CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition Advances in immunotherapy for treatment of lung cancer Human Cancer Immunotherapy with PD-1/PD-L1 Blockade Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing Role of the PD-1 pathway in the immune response The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity Immune Checkpoint Blockade in Cancer Therapy Tempering allorecognition to induce transplant tolerance with chemically modified apoptotic donor cells Therapeutic cancer vaccines: past, present, and future Molecular mechanisms of T cell co-stimulation and co-inhibition Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response New immunotherapies targeting the PD-1 pathway Nanoengineering approaches to the design of artificial antigen-presenting cells Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2 Structure and Interactions of the Human Programmed Cell Death 1 Receptor The blockade of immune checkpoints in cancer immunotherapy Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Targeting immune checkpoints in malignant glioma PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations Immune checkpoint therapy for pancreatic cancer Pembrolizumab in classical Hodgkin's lymphoma Immune checkpoint blockade: a common denominator approach to cancer therapy The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma The role of the PD-1 pathway in autoimmunity and peripheral tolerance Mechanisms of action of therapeutic antibodies for cancer Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy

P2860

Q21089831-86DD2802-59D4-4550-A3CF-3039BA5868A5 Q21143804-8B3E0AB7-BB80-4A71-A9C1-619076A8D3D4 Q24633549-68E0E339-DD38-4C51-AE31-A541EAA0EC57 Q24655393-8291B697-D8F4-4BB6-92B4-4765B27CECEE Q24655516-8348E263-B316-40B9-AB24-93037A029C5F Q26738729-434C74E8-48CC-4EEB-A69C-EF1A4317D394 Q26745516-10A9E54C-5E46-4822-B226-A08441E66438 Q26752513-AC7C0980-88E8-4446-BE59-FB992575D7A1 Q26769728-49A77DE7-5B04-4F86-A4F7-D0814B8D6F9B Q26769734-28266057-3ED1-49FA-8117-2C6718D6AE1E Q26775591-29018F55-DFFC-4D45-BEFA-9E8D1E3481D1 Q26777563-36FD7CE2-7985-45EC-BC02-DAA194359FA7 Q26778790-9CC5A6E1-2DA6-468C-BE45-E96CD848FB17 Q26786108-21AF71E1-BD48-4758-8131-5237254F3B93 Q26798047-57F031F9-32C9-488D-AD66-73C864D91B9A Q26825644-D04C9838-A37B-4CB4-AA97-344F2B9B49D5 Q26828748-C8829169-8698-4A2C-9657-17A72F99619D Q26829847-8EF03326-4224-425D-954F-06596C16DFE5 Q26830509-2F646537-1FAE-4DEC-8413-4DED67AF05F5 Q26851647-BF567929-800A-49D7-91E8-F0FFAF0B9482 Q26863283-6C7F7883-A17F-4A44-9A20-953BD0862E67 Q26864888-E05FE655-F94A-4FB2-BCB3-C4A0CEC4E529 Q26996330-AFFA637A-9D77-44F4-ADC2-5EAC96EE9EFF Q27010018-D8C431F5-EEE1-4997-9378-7328F52704E8 Q27023634-6B6C792A-0BC2-4EA4-BD69-88ECB9F47B1C Q27340853-BD21BB75-C81F-48B3-970A-EE21CA5FA2E2 Q27649885-273902FE-8A8B-45F6-997C-332748372C3B Q27651269-06FAA263-9BE4-42E8-B280-49A196C218F9 Q27676419-77FD651A-5157-49D2-AE78-3B931B8EF30F Q27860852-600DE0BD-4540-4CC9-8ACC-C62E07D2358A Q27860857-F73F3273-C297-4891-BD0A-C53EFB29455F Q28072012-097B3BBB-A6FF-42F8-90BF-00E2150579CF Q28075712-70AA9BDB-59BD-4709-9281-46C6F513526A Q28078390-082FEBEB-8825-4739-B38E-CAADF4A451DD Q28079273-E74201A9-F14E-4CAF-8FBF-5C60E5B89396 Q28083981-43BD5712-A341-4CAB-AF34-7E82A02931EF Q28088496-AF9B0AED-70CC-477F-B7CE-E16396B0240A Q28304161-CC9FCE3D-36B7-46BC-BC00-B9A2C6B99073 Q28385366-54A7958C-BDA6-412D-97B0-277A43BCB829 Q28394869-4D2C0123-1489-4D0C-A782-3DAE20AD139B

P2860

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

http://www.wikidata.org/entity/Q34650346

description

2007 nî lūn-bûn

@nan

2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

name

Programmed death-1 ligand 1 in ...... e to inhibit T cell responses.

@ast

Programmed death-1 ligand 1 in ...... e to inhibit T cell responses.

@en

Programmed death-1 ligand 1 in ...... e to inhibit T cell responses.

@nl

type

label

Programmed death-1 ligand 1 in ...... e to inhibit T cell responses.

@ast

Programmed death-1 ligand 1 in ...... e to inhibit T cell responses.

@en

Programmed death-1 ligand 1 in ...... e to inhibit T cell responses.

@nl

prefLabel

Programmed death-1 ligand 1 in ...... e to inhibit T cell responses.

@ast

Programmed death-1 ligand 1 in ...... e to inhibit T cell responses.

@en

Programmed death-1 ligand 1 in ...... e to inhibit T cell responses.

@nl

P1433

Q34650346-18D18CB6-C035-4464-BCAB-196BCE43AB36

P1476

Q34650346-BB9CC517-4365-4769-A83E-7F7083134A12

P2093

Q34650346-225267D7-6408-463A-90D9-D9382E41A729

Q34650346-2564AF46-725A-4752-BA37-A6B4436FC81A

Q34650346-948082A2-67F7-425D-9342-3EBFD6E86A92

Q34650346-A3975034-1DD9-41D6-941D-6EEAE569A1EF

P2860

Q34650346-06E88964-10AB-4360-85EB-0CD9AAB4A61A

Q34650346-0D23F7A3-6AAA-41A9-A00C-E4D45684635F

Q34650346-0F461DD3-C1D7-408F-923E-F1D9F05649AC

Q34650346-11FDF48F-3636-41FF-9267-B97B6970D583

Q34650346-15DB5310-AAE0-496F-ADF1-9723119DF42E

Q34650346-15E1E359-6AC7-498E-86B7-6B6885BACF1D

Q34650346-1623C00C-E37A-4511-917B-7C503AA5BB2F

Q34650346-17678812-10B9-4592-86ED-306392BC2456

Q34650346-197B2D67-94A9-4656-8BA0-C0A983C3EF10

Q34650346-2400FFF5-6A4F-4D7C-A114-5B996F04C924

P304

Q34650346-88AF0CA1-A4DA-489F-8060-90C23BB1BEAF

P31

Q34650346-D58111A0-8783-42C4-A392-BE18FD02E0C9

P356

Q34650346-DCF9B39D-F52C-45C8-B5F3-1BB92CE55B05

P407

Q34650346-68866F8B-22EA-44D9-B7BC-6F14C4DCDC8A

P433

Q34650346-C1AEC383-06EC-4803-8F38-C97ACA985BD8

P478

Q34650346-1080B290-57EB-4CD2-928B-2ADC7B79DAA7

P50

Q34650346-ABD0D51B-F2C7-4D30-9B1F-85F62D4C9BAD

P577

Q34650346-E3D05207-16D6-4E35-8FA4-55A4E1BF91BB

P5875

Q34650346-3ECFC95C-9E46-4494-B30B-56B92BF7D62C

P698

Q34650346-8650529E-375C-417D-884F-4DF3C1558760

P932

Q34650346-207DF89B-79B9-4E2A-AC5B-5A760FE9D7E3

P356

J.IMMUNI.2007.05.016

P1433

P1476

Programmed death-1 ligand 1 in ...... e to inhibit T cell responses.

@en

P2093

Arlene H Sharpe

http://www.w3.org/2001/XMLSchema#string

Gordon J Freeman

http://www.w3.org/2001/XMLSchema#string

Mary E Keir

http://www.w3.org/2001/XMLSchema#string

Theresa B Phamduy

http://www.w3.org/2001/XMLSchema#string

P2860

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Structural basis for co-stimulation by the human CTLA-4/B7-2 complex

Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors

Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion

Structure and dimerization of a soluble form of B7-1

Comparative protein modelling by satisfaction of spatial restraints

P304

111-122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IMMUNI.2007.05.016

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Manish J. Butte

P577

2007-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6207743

http://www.w3.org/2001/XMLSchema#string

P698

17629517

http://www.w3.org/2001/XMLSchema#string

P932

2707944

http://www.w3.org/2001/XMLSchema#string